OncoMatch/Clinical Trials/NCT04665206
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Is NCT04665206 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including VT3989 and Nivolumab & Ipilimumab for solid tumor, adult.
Treatment: VT3989 · Nivolumab & Ipilimumab · Osimertinib — This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Mesothelioma
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR ex19del
NSCLC with exon 19 deletions or exon 21 L858R mutations
Required: EGFR L858R
NSCLC with exon 19 deletions or exon 21 L858R mutations
Disease stage
Required: Stage III, IV
metastatic or unresectable malignant mesothelioma; incurable locally advanced (inoperable or recurrent), or metastatic NSCLC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: TEAD inhibitor
Exception: except for EHE patients
Prior treatment with TEAD inhibitor, except for EHE patients.
Lab requirements
Blood counts
adequate organ functions, including the hematopoietic system
Kidney function
adequate organ functions, including the kidneys
Liver function
adequate organ functions, including the liver
Cardiac function
QTcF interval ≤ 470 msec (except for Part 2 Expansion Cohort 3, where ≤ 450 msec)
Adequate organ functions, including the liver, kidneys, and hematopoietic system. Corrected QT (QTcF) interval > 470 msec (using Fridericia's correction formula); except for Part 2 Expansion Cohort 3, the QTcF interval criteria is > 450 msec). Clinically significant cardiovascular disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCSF Helen Diller Family Comprehensive Cancer Center · San Francisco, California
- University of Chicago Medical Center · Chicago, Illinois
- Massachusetts General Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
- M Health Fairview University of Minnesota Medical Center · Minneapolis, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify